| Name | Title | Contact Details |
|---|
Ness Digital Engineering designs and builds digital platforms and software that help organizations engage customers, differentiate their brands, and drive revenue growth. Our customer experience designers, software engineers and data experts partner with clients to develop roadmaps that identify ongoing opportunities to increase the value of their digital products and services. Through agile development of minimum viable products (MVPs), our clients can test new ideas in the market and continually adapt to changing business conditions—giving our clients the leverage to lead market disruption in their industries and compete more effectively to drive revenue growth.
The right mindset changes everything
Cima Technology is a Hong Kong, PR-based company in the Software and Internet sector.
Juvo was founded with an overarching mission: to empower the billions of unbanked people around the world to create financial identities and access financial services - all through their everyday interactions with their mobile phone. In partnership with mobile network operators, Juvo`s proprietary Identity Scoring technology uses data science, machine learning and game mechanics to create an identity-based relationship with anonymous prepaid users, opening up access to otherwise unattainable mobile financial services.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.